183 related articles for article (PubMed ID: 30429879)
21. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
[TBL] [Abstract][Full Text] [Related]
22. Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.
Devi L; Tang J; Ohno M
Curr Alzheimer Res; 2015; 12(1):13-21. PubMed ID: 25523425
[TBL] [Abstract][Full Text] [Related]
23. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
24. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Imbimbo BP; Watling M
Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
[No Abstract] [Full Text] [Related]
25. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.
Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD
Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226
[TBL] [Abstract][Full Text] [Related]
26. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
Devi L; Ohno M
Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
[TBL] [Abstract][Full Text] [Related]
27. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.
Fukumoto H; Takahashi H; Tarui N; Matsui J; Tomita T; Hirode M; Sagayama M; Maeda R; Kawamoto M; Hirai K; Terauchi J; Sakura Y; Kakihana M; Kato K; Iwatsubo T; Miyamoto M
J Neurosci; 2010 Aug; 30(33):11157-66. PubMed ID: 20720123
[TBL] [Abstract][Full Text] [Related]
28. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
[TBL] [Abstract][Full Text] [Related]
29. Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.
Chiocco MJ; Kulnane LS; Younkin L; Younkin S; Evin G; Lamb BT
J Biol Chem; 2004 Dec; 279(50):52535-42. PubMed ID: 15452128
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.
O'Connor T; Sadleir KR; Maus E; Velliquette RA; Zhao J; Cole SL; Eimer WA; Hitt B; Bembinster LA; Lammich S; Lichtenthaler SF; Hébert SS; De Strooper B; Haass C; Bennett DA; Vassar R
Neuron; 2008 Dec; 60(6):988-1009. PubMed ID: 19109907
[TBL] [Abstract][Full Text] [Related]
31. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
32. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
Hook G; Yu J; Toneff T; Kindy M; Hook V
J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
[TBL] [Abstract][Full Text] [Related]
33. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease.
He P; Cheng X; Staufenbiel M; Li R; Shen Y
PLoS One; 2013; 8(2):e55091. PubMed ID: 23405115
[TBL] [Abstract][Full Text] [Related]
34. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
[TBL] [Abstract][Full Text] [Related]
35. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Johnson ECB; Ho K; Yu GQ; Das M; Sanchez PE; Djukic B; Lopez I; Yu X; Gill M; Zhang W; Paz JT; Palop JJ; Mucke L
Mol Neurodegener; 2020 Sep; 15(1):53. PubMed ID: 32921309
[TBL] [Abstract][Full Text] [Related]
36. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.
Brendel M; Jaworska A; Grießinger E; Rötzer C; Burgold S; Gildehaus FJ; Carlsen J; Cumming P; Baumann K; Haass C; Steiner H; Bartenstein P; Herms J; Rominger A
PLoS One; 2015; 10(2):e0116678. PubMed ID: 25706990
[TBL] [Abstract][Full Text] [Related]
37. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
[TBL] [Abstract][Full Text] [Related]
38. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
Zhao J; Fu Y; Yasvoina M; Shao P; Hitt B; O'Connor T; Logan S; Maus E; Citron M; Berry R; Binder L; Vassar R
J Neurosci; 2007 Apr; 27(14):3639-49. PubMed ID: 17409228
[TBL] [Abstract][Full Text] [Related]
39. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
40. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
